Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) [clinicaltrials:NCT00127777]
Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) [clinicaltrials:NCT00127777]
Bio2RDF identifier
NCT00127777
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00127777
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This was a randomized, ...... ent standard
treatment.
brief title [clinicaltrials_vocabulary:brief-title]
Peginterferon Alfa-2a, Ribavir ...... )-Genotype-1-Infection (PRAMA)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2006-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
detailed description [clinicaltrials_vocabulary:detailed-description]
Primary Objective:
...... es at the end of the therapy.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-08-04T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
HCV genotype 1
amantadine
peginterferon alfa-2a
treatment-naive
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-08-24T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00127777
official title [clinicaltrials_vocabulary:official-title]
Randomized, Multi-Center, Part ...... s C Virus-Genotype-1-Infection
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2002-07-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2005-08-01T00:00:00Z
identifier
clinicaltrials:NCT00127777
title
Peginterferon Alfa-2a, Ribavir ...... )-Genotype-1-Infection (PRAMA)
@en
type
label
Peginterferon Alfa-2a, Ribavir ...... ) [clinicaltrials:NCT00127777]
@en